ATE504308T1 - Antimikrobielle kationische peptide und diese enthaltende formulierungen - Google Patents

Antimikrobielle kationische peptide und diese enthaltende formulierungen

Info

Publication number
ATE504308T1
ATE504308T1 AT02759416T AT02759416T ATE504308T1 AT E504308 T1 ATE504308 T1 AT E504308T1 AT 02759416 T AT02759416 T AT 02759416T AT 02759416 T AT02759416 T AT 02759416T AT E504308 T1 ATE504308 T1 AT E504308T1
Authority
AT
Austria
Prior art keywords
antimicrobial cationic
cationic peptides
formulations containing
containing same
infections
Prior art date
Application number
AT02759416T
Other languages
English (en)
Inventor
Timothy Krieger
Patricia Mcnicol
Original Assignee
Migenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Migenix Inc filed Critical Migenix Inc
Application granted granted Critical
Publication of ATE504308T1 publication Critical patent/ATE504308T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT02759416T 2001-08-21 2002-08-21 Antimikrobielle kationische peptide und diese enthaltende formulierungen ATE504308T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31423201P 2001-08-21 2001-08-21
US10/225,087 US6835536B2 (en) 2001-08-21 2002-08-20 Antimicrobial cationic peptides and formulations thereof
PCT/US2002/026525 WO2003015809A2 (en) 2001-08-21 2002-08-21 Antimicrobial cationic peptides and formulations thereof

Publications (1)

Publication Number Publication Date
ATE504308T1 true ATE504308T1 (de) 2011-04-15

Family

ID=26919289

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02759416T ATE504308T1 (de) 2001-08-21 2002-08-21 Antimikrobielle kationische peptide und diese enthaltende formulierungen

Country Status (8)

Country Link
US (5) US6835536B2 (de)
EP (1) EP1469876B1 (de)
JP (3) JP4932136B2 (de)
AT (1) ATE504308T1 (de)
AU (1) AU2002324752B2 (de)
CA (1) CA2456477C (de)
DE (1) DE60239707D1 (de)
WO (1) WO2003015809A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550558B2 (en) * 2001-06-01 2009-06-23 Fundacao De Ampara A Pesquiso Do Estado De Sao Paolo (Fapesp) Antimicrobial peptides and methods for identifying and using such peptides
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
WO2003018619A2 (en) * 2001-08-24 2003-03-06 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
US7507787B2 (en) * 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
US20030144362A1 (en) * 2002-01-28 2003-07-31 Utterberg David S. High viscosity antibacterials for cannulae
US20060128614A1 (en) * 2002-09-20 2006-06-15 Jya-Wei Cheng Antimicrobial peptides with reduced hemolysis and methods of their use
BRPI0413521A (pt) 2003-08-14 2006-10-10 Diatos seqüências de aminoácidos que facilitam a penetração de uma substáncia de interesse nas células e/ou no núcleos celulares
WO2005019241A2 (en) * 2003-08-18 2005-03-03 E.I. Dupont De Nemours And Company Cationic antimicrobial peptides and compositions thereof
JP2007505048A (ja) * 2003-09-12 2007-03-08 ザ ユニバーシティー オブ ブリティッシュ コロンビア 先天性免疫のエフェクターの決定方法
KR20070024558A (ko) * 2004-05-27 2007-03-02 산텐 세이야꾸 가부시키가이샤 안과용 점조화제
JP4736540B2 (ja) * 2004-05-27 2011-07-27 参天製薬株式会社 眼科用粘稠化剤
CA2629751A1 (en) * 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
BRPI0614530A2 (pt) * 2005-08-01 2011-08-09 Univ Louisiana State uso de um peptìdeo, peptìdeo, composição farmacêutica, e, ácido nucleico
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US7902327B2 (en) 2007-05-22 2011-03-08 New York University School Of Medicine Dendrimeric peptides, pharmaceutical compositions and methods of using the same
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
US20100055158A1 (en) * 2008-08-28 2010-03-04 Tyco Healthcare Group Lp Environmentally Activated Compositions, Articles and Methods
US20120213843A1 (en) * 2009-11-03 2012-08-23 Lipidor Ab Composition for promoting wound healing
US8916171B2 (en) 2010-04-27 2014-12-23 Topical Sinus Therapeutics, Inc. Topical delivery of viscous medications for the treatment of diseases associated with chronic sinusitis
US8986399B2 (en) * 2011-05-25 2015-03-24 Empire Technology Development Llc Treating lignocellulosic materials
EP3384938A1 (de) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Manipulierte nukleinsäuren und verfahren zur verwendung davon
JP5894457B2 (ja) * 2012-02-22 2016-03-30 株式会社Adeka ペプチド含有抗菌性組成物
JP6224069B2 (ja) 2012-03-23 2017-11-01 アミクローブ，インコーポレイテッド 組織適合特性を有する抗菌剤の組成物および使用
EP2834259A4 (de) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Modifizierte polynukleotide
HK1206612A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
EP3374391B1 (de) 2015-11-10 2024-04-17 Visterra, Inc. Antikörpermolekülarzneimittelkonjugate die an lipopolysaccharide binden und verwendungen davon
WO2017140770A1 (en) * 2016-02-19 2017-08-24 Forschungszentrum Borstel Leibniz-Zentrum Für Medizin Und Biowissenschaften Means and methods for treating bacterial infections
JP7303110B2 (ja) 2017-01-18 2023-07-04 ビステラ， インコーポレイテッド 抗体分子－薬物コンジュゲートおよびその使用
WO2018143911A1 (en) 2017-01-31 2018-08-09 Kimberly-Clark Worldwide, Inc. Antibacterial composition including benzoic acid ester and methods of inhibiting bacterial growth utilizing the same
US11021529B2 (en) 2017-03-03 2021-06-01 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
WO2018187617A1 (en) 2017-04-06 2018-10-11 Amicrobe, Inc. Compositions and uses of locally applied antimicrobials with enhanced performance and safety
EP3703493A4 (de) 2017-10-30 2022-01-12 Allvivo Vascular, Inc. Abgabesysteme zur verabreichung von kationischen biologischen wirkstoffen
WO2020162582A1 (en) * 2019-02-08 2020-08-13 Maruho Co., Ltd. Methods of treating non-virally-induced cancers
US12144910B2 (en) 2019-04-16 2024-11-19 Academia Sinica Methods of coating antimicrobial peptides on the biomaterial and the biomaterial coated thereby
EP3797800A1 (de) * 2019-05-02 2021-03-31 Institut National De La Sante Et De La Recherche Medicale - Inserm Hyaluronsäurehydrogele mit verlängerter antimikrobieller wirkung
JP2023501385A (ja) * 2019-11-08 2023-01-18 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 抗微生物ペプチドを含む組成物
US11969476B2 (en) 2020-04-03 2024-04-30 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CZ309857B6 (cs) 2022-03-31 2023-12-20 Contipro A.S. Hexapeptid, kompozice zahrnující tento hexapeptid a jejich topické použití

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
US4816449A (en) 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
JPH0645535B2 (ja) * 1987-05-20 1994-06-15 サンスタ−株式会社 歯槽骨代謝治療用組成物
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US4956184A (en) 1988-05-06 1990-09-11 Alcide Corporation Topical treatment of genital herpes lesions
NZ237202A (en) 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
US5776892A (en) 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
WO1992015286A1 (en) 1991-02-27 1992-09-17 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
US5324716A (en) 1991-06-14 1994-06-28 Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5547939A (en) 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
JPH07507213A (ja) 1992-05-22 1995-08-10 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 消化器デフェンシン，そのｃＤＮＡ配列及び製造方法並びにその使用
US5593866A (en) 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
ES2079994B1 (es) 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
GB9224598D0 (en) 1992-11-24 1993-01-13 Smithkline Beecham Plc Novel compositions
US5436222A (en) 1993-03-15 1995-07-25 The Research Foundation Of State University Of New York Use of platelet factor 4 to treat inflammatory diseases
US5459235A (en) 1993-03-19 1995-10-17 The Regents Of The University Of California Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
DE69430823T2 (de) 1993-09-22 2003-02-20 Xoma Technology Ltd., Berkeley Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
PT754050E (pt) 1994-01-14 2002-11-29 Xoma Technology Ltd Metodos e materiais contra bacterias gram-positivas
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5505949A (en) 1994-10-13 1996-04-09 Benitez; Juan E. Topical treatment for acne
US5834430A (en) 1995-05-31 1998-11-10 Biosynth S.R.L. Potentiation of antibiotics
US5877274A (en) 1995-06-02 1999-03-02 University Of British Columbia Antimicrobial cationic peptides
US6057291A (en) * 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
DE69637731D1 (de) 1995-08-23 2008-12-11 Univ British Columbia Antimikrobielle kationische peptide und methoden zu ihrer identifizierung
US5994308A (en) 1996-02-28 1999-11-30 Board Of Trustees Of Southern Illinois University Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6551994B1 (en) 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin
US5997893A (en) 1998-01-20 1999-12-07 Ethicon, Inc. Alcohol based anti-microbial compositions with cosmetic appearance
US6248343B1 (en) 1998-01-20 2001-06-19 Ethicon, Inc. Therapeutic antimicrobial compositions
AU2605099A (en) 1998-02-25 1999-09-15 Micrologix Biotech, Inc. Indolicidin and cationic peptides conjugated with polymers
US6303575B1 (en) 1998-05-12 2001-10-16 The Regents Of The University Of California Indolicidin analogs and methods of using same
WO1999065506A2 (en) 1998-06-12 1999-12-23 Micrologix Biotech Inc. Cancer therapy with indolicidin or cationic peptides and their polymer conjugates
US6444645B1 (en) 1998-06-18 2002-09-03 The Regents Of The University Of California Crosslink-stabilized indolicidin analogs
NZ509101A (en) 1998-06-26 2003-07-25 N Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
EP1152744B1 (de) * 1999-02-12 2004-08-18 The Procter & Gamble Company Zusammensetzung zur hautdesinfizierung
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
CA2375829A1 (en) * 1999-06-02 2000-12-07 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof

Also Published As

Publication number Publication date
WO2003015809A2 (en) 2003-02-27
DE60239707D1 (de) 2011-05-19
JP2005504769A (ja) 2005-02-17
US8138144B2 (en) 2012-03-20
US20120202735A1 (en) 2012-08-09
US9227999B2 (en) 2016-01-05
WO2003015809A9 (en) 2004-04-22
US20130296227A1 (en) 2013-11-07
US8927487B2 (en) 2015-01-06
CA2456477A1 (en) 2003-02-27
EP1469876A2 (de) 2004-10-27
CA2456477C (en) 2016-02-16
JP2015028082A (ja) 2015-02-12
EP1469876B1 (de) 2011-04-06
AU2002324752B2 (en) 2008-07-03
US6835536B2 (en) 2004-12-28
US20030171281A1 (en) 2003-09-11
JP2012041367A (ja) 2012-03-01
JP4932136B2 (ja) 2012-05-16
JP5684098B2 (ja) 2015-03-11
US20150087580A1 (en) 2015-03-26
US20050049182A1 (en) 2005-03-03
WO2003015809A3 (en) 2004-03-18
US8466102B2 (en) 2013-06-18

Similar Documents

Publication Publication Date Title
ATE504308T1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
BR0308090A (pt) conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
BR0115531A (pt) Tratamento de mucosites
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
MXPA03009772A (es) Metodos y composiciones para tratar lesiones orales y del esofago.
IS5591A (is) Grunnmassaprótínsamsetningar til sáragræðslu
DE60312211D1 (de) Haarbehandlungsmittel
SE9904377D0 (sv) Pharmaceutical combinations
EA199900246A1 (ru) Фармацевтические соединения
NO20073914L (no) Biologisk aktive peptider
WO2004041158A3 (en) Rifalazil compositions and therapeutic regimens
SE0003476D0 (sv) Compounds
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
PL368040A1 (en) Substituted 4-aminocyclohexanol derivatives
AU2003206144A1 (en) Pharmaceutical composition for cancer treatment containing p43 protein and paclitaxel, therapy method using the same and use thereof
WO2003053959A8 (de) Heterocyclylaminocarbo nyluracile
WO2002100342A3 (en) (s, s'), (s, r')-amphetaminil, compositions and uses thereof
WO2002100346A3 (en) (r, r'),(r',s')-amphetaminil, compositions and uses thereof
UA32314A (uk) Спосіб лікування некротичного панкреатиту

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties